Tissue-based biomarkers in prostate cancer

Timothy N. Clinton, Aditya Bagrodia, Yair Lotan, Vitaly Margulis, Ganesh Raj, Solomon L. Woldu

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Introduction: Prostate cancer is a heterogeneous disease. Existing risk stratification tools based on standard clinlicopathologic variables (prostate specific antigen [PSA], Gleason score, and tumor stage) provide a modest degree of predictive ability. Advances in high-throughput sequencing has led to the development of several novel tissue-based biomarkers that can improve prognostication in prostate cancer management. Areas covered: The authors review commercially-available, tissue-based biomarker assays that improve upon existing risk-stratification tools in several areas of prostate cancer management, including the appropriateness of active surveillance and aiding in decision making regarding the use of adjuvant therapy. Additionally, some of the obstacles to the widespread adoption of these biomarkers and discuss several investigational sources of new biomarkers are discussed. Expert commentary: Work is ongoing to answer pertinent clinical questions in prostate cancer management including which patients should undergo biopsy, active surveillance, receive adjuvant therapy, and what systemic therapy is best in the first-line. Incorporation into novel biomarkers may allow for the incorporation of a ‘personalized’ approach to management. Further validation will be required and questions of cost must be considered before wide scale adoption of these biomarkers. Tumor heterogeneity may impose a ceiling on the prognostic ability of biomarkers using currently available techniques.

Original languageEnglish (US)
Pages (from-to)249-260
Number of pages12
JournalExpert Review of Precision Medicine and Drug Development
Volume2
Issue number5
DOIs
StatePublished - Jan 1 2017

Fingerprint

Prostatic Neoplasms
Biomarkers
Aptitude
Neoplasm Grading
Prostate-Specific Antigen
Neoplasms
Decision Making
Therapeutics
Biopsy
Costs and Cost Analysis

Keywords

  • Active surveillance
  • Adjuvant therapy
  • Biomarker
  • Genomics
  • Prostate cancer

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Tissue-based biomarkers in prostate cancer. / Clinton, Timothy N.; Bagrodia, Aditya; Lotan, Yair; Margulis, Vitaly; Raj, Ganesh; Woldu, Solomon L.

In: Expert Review of Precision Medicine and Drug Development, Vol. 2, No. 5, 01.01.2017, p. 249-260.

Research output: Contribution to journalReview article

@article{27c9c84d94a94d949868ab22fb3c68b8,
title = "Tissue-based biomarkers in prostate cancer",
abstract = "Introduction: Prostate cancer is a heterogeneous disease. Existing risk stratification tools based on standard clinlicopathologic variables (prostate specific antigen [PSA], Gleason score, and tumor stage) provide a modest degree of predictive ability. Advances in high-throughput sequencing has led to the development of several novel tissue-based biomarkers that can improve prognostication in prostate cancer management. Areas covered: The authors review commercially-available, tissue-based biomarker assays that improve upon existing risk-stratification tools in several areas of prostate cancer management, including the appropriateness of active surveillance and aiding in decision making regarding the use of adjuvant therapy. Additionally, some of the obstacles to the widespread adoption of these biomarkers and discuss several investigational sources of new biomarkers are discussed. Expert commentary: Work is ongoing to answer pertinent clinical questions in prostate cancer management including which patients should undergo biopsy, active surveillance, receive adjuvant therapy, and what systemic therapy is best in the first-line. Incorporation into novel biomarkers may allow for the incorporation of a ‘personalized’ approach to management. Further validation will be required and questions of cost must be considered before wide scale adoption of these biomarkers. Tumor heterogeneity may impose a ceiling on the prognostic ability of biomarkers using currently available techniques.",
keywords = "Active surveillance, Adjuvant therapy, Biomarker, Genomics, Prostate cancer",
author = "Clinton, {Timothy N.} and Aditya Bagrodia and Yair Lotan and Vitaly Margulis and Ganesh Raj and Woldu, {Solomon L.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1080/23808993.2017.1372687",
language = "English (US)",
volume = "2",
pages = "249--260",
journal = "Expert Review of Precision Medicine and Drug Development",
issn = "2380-8993",
publisher = "Taylor and Francis Ltd.",
number = "5",

}

TY - JOUR

T1 - Tissue-based biomarkers in prostate cancer

AU - Clinton, Timothy N.

AU - Bagrodia, Aditya

AU - Lotan, Yair

AU - Margulis, Vitaly

AU - Raj, Ganesh

AU - Woldu, Solomon L.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Introduction: Prostate cancer is a heterogeneous disease. Existing risk stratification tools based on standard clinlicopathologic variables (prostate specific antigen [PSA], Gleason score, and tumor stage) provide a modest degree of predictive ability. Advances in high-throughput sequencing has led to the development of several novel tissue-based biomarkers that can improve prognostication in prostate cancer management. Areas covered: The authors review commercially-available, tissue-based biomarker assays that improve upon existing risk-stratification tools in several areas of prostate cancer management, including the appropriateness of active surveillance and aiding in decision making regarding the use of adjuvant therapy. Additionally, some of the obstacles to the widespread adoption of these biomarkers and discuss several investigational sources of new biomarkers are discussed. Expert commentary: Work is ongoing to answer pertinent clinical questions in prostate cancer management including which patients should undergo biopsy, active surveillance, receive adjuvant therapy, and what systemic therapy is best in the first-line. Incorporation into novel biomarkers may allow for the incorporation of a ‘personalized’ approach to management. Further validation will be required and questions of cost must be considered before wide scale adoption of these biomarkers. Tumor heterogeneity may impose a ceiling on the prognostic ability of biomarkers using currently available techniques.

AB - Introduction: Prostate cancer is a heterogeneous disease. Existing risk stratification tools based on standard clinlicopathologic variables (prostate specific antigen [PSA], Gleason score, and tumor stage) provide a modest degree of predictive ability. Advances in high-throughput sequencing has led to the development of several novel tissue-based biomarkers that can improve prognostication in prostate cancer management. Areas covered: The authors review commercially-available, tissue-based biomarker assays that improve upon existing risk-stratification tools in several areas of prostate cancer management, including the appropriateness of active surveillance and aiding in decision making regarding the use of adjuvant therapy. Additionally, some of the obstacles to the widespread adoption of these biomarkers and discuss several investigational sources of new biomarkers are discussed. Expert commentary: Work is ongoing to answer pertinent clinical questions in prostate cancer management including which patients should undergo biopsy, active surveillance, receive adjuvant therapy, and what systemic therapy is best in the first-line. Incorporation into novel biomarkers may allow for the incorporation of a ‘personalized’ approach to management. Further validation will be required and questions of cost must be considered before wide scale adoption of these biomarkers. Tumor heterogeneity may impose a ceiling on the prognostic ability of biomarkers using currently available techniques.

KW - Active surveillance

KW - Adjuvant therapy

KW - Biomarker

KW - Genomics

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85053420990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053420990&partnerID=8YFLogxK

U2 - 10.1080/23808993.2017.1372687

DO - 10.1080/23808993.2017.1372687

M3 - Review article

VL - 2

SP - 249

EP - 260

JO - Expert Review of Precision Medicine and Drug Development

JF - Expert Review of Precision Medicine and Drug Development

SN - 2380-8993

IS - 5

ER -